John Moscariello

John Moscariello currently serves as the executive director of Gene Delivery Process and Analytical Development at Bristol-Myers Squibb. At BMS, his group is responsible for the process and analytical development of the viral vectors and gene editing materials required for the clinical and commercial cellular products, including Breyanzi® and Abecma®. Prior to BMS, he was the Vice President of Process Development at AGC Biologics, where his team was responsible for cell line development, upstream and downstream process development, analytical and formulation development, and manufacturing technical support for AGC Biologic’s US-based clinical and commercial manufacturing facilities. His team supported development activities for Toxicology/Phase 1 supply up to and including commercialization and post-approval process support. Before AGC Biologics, Moscariello had functional leadership positions in process development and process engineering at Amgen. Moscariello has a strong track record in evaluating and implementing new technologies. Throughout his career, Moscariello has been a member of various scientific advisory boards and is currently a board observer for a start-up cellular therapy company. Moscariello is very active in the scientific community as an invited lecturer on CMC challenges for biologics and cell and therapy products to the annual Drug Development Boot Camp, an adjunct faculty member at the University of Washington, and was previously an ACS BIOT officer. Additionally, Moscariello was the downstream area coordinator for the ACS conference and has chaired sessions at the Recovery of Biologics, the Phacilitate Leaders World Summit, as well as various BioProcess International and CBI conferences. Moscariello obtained his PhD in Chemical and Biological Engineering from the University of Wisconsin-Madison and his B.Eng. in Chemical Engineering from the University of Delaware.